Small Molecules

05 Aug 2019 AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
04 Aug 2019 Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
04 Aug 2019 FDA Approves Daiichi Sankyo's TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
04 Aug 2019 AbbVie's MAVIRET™ (glecaprevir/pibrentasvir) Approved by European Commission to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
04 Aug 2019 Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis
01 Aug 2019 Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
01 Aug 2019 AZTherapies Completes Enrollment in COGNITE Pivotal Phase 3 Trial of ALZT-OP1 for the Treatment of Early Alzheimer’s Disease
01 Aug 2019 LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar® Foam and Taclonex® Topical Suspension in Treatment of Plaque Psoriasis
01 Aug 2019 Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cystic Fibrosis Foundation (CFF)
01 Aug 2019 Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial
31 Jul 2019 Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
31 Jul 2019 Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia
31 Jul 2019 Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors
31 Jul 2019 Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
31 Jul 2019 Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials
31 Jul 2019 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
31 Jul 2019 U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer
30 Jul 2019 Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
30 Jul 2019 Fatality in Phase I Clinical Study of E2082
30 Jul 2019 Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
30 Jul 2019 Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder
30 Jul 2019 Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH
30 Jul 2019 Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
30 Jul 2019 Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
29 Jul 2019 Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top